Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for external preparation for skin

a technology of external preparation and composition, which is applied in the direction of peptide/protein ingredients, extracellular fluid disorder, immunological disorders, etc., can solve the problems of repeated inappropriate external application, rebound phenomenon induced by discontinuation of external application, and difficult application to areas of high drug absorbability such as the face, and achieves the effects of improving erythema, papules and scales, and little inflammatory

Inactive Publication Date: 2012-08-16
IGISU
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The invention aims to provide a safe and effective skin external preparation for patients with dermatitis, particularly atopic dermatitis. The preparation is suitable for use on the face and neck, as well as patients with sensitive skin, children, and females. It also includes a skin texture-improving agent to enhance the skin's barrier functions, prevent recurrence, and improve skin appearance. The preparation has anti-inflammatory properties and cares for the skin's layers and membrane."

Problems solved by technology

While steroid external preparations produce satisfactory clinical effects as stated above, they also have many adverse local effects, including skin thinning and atrophy, moon face, skin flush, hirsutism, and skin striae, hence their application to areas of high drug absorbability such as the face, and to patients with sensitive skin, children and females, has been difficult.
In addition to the problem of adverse local effects, the repeated and long-term use of topical steroids, which is necessary in many cases due to the chronic nature of atopic dermatitis, can lead to rebound phenomena induced by discontinuation of external application.
In addition, as more serious complications, erythroderma posteczematosa with whole-body skin flush and desquamation can result from continuous inappropriate external application.
These severe symptoms induced by a long-term use of steroids have been a serious problem.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for external preparation for skin
  • Composition for external preparation for skin
  • Composition for external preparation for skin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Diagnosis and Evaluation of Subjects

[0180]First, prior to administration of the CNP preparation or BNP preparation of the present invention, subjects were diagnosed and evaluated. The methods for diagnosis and evaluation of the subjects are as follows.

1. Diagnosis of Subjects:

[0181]All the subjects were patients for whom administration of existing external drugs such as steroids, etc. was ineffective. The diagnosis and treatment of these subjects were performed by the present inventor as a medical doctor.

2. Evaluation of Symptoms:

[0182]The evaluation of symptoms of atopic dermatitis was performed in accordance with, in principle, “2005 Guideline for the Treatment of Atopic Dermatitis by the Scientific Research Division of the Health and Welfare Ministry of Japan” (hereinafter, simply referred to as “Guideline 2005”) by the classification into four levels as shown in Table 1.

TABLE 1Evaluation of symptomsMildOnly mild rash is observed regardless of size.ModerateRash with severe inflam...

example 2

1. Production of CNP Gel Preparation

[0186]0.1 g of methyl parahydroxybenzoate (product name: Mekkins M, Ueno Fine Chemicals Industry), 0.2 g of phenoxyethanol, 3.0 g of 1,2-pentanediol, 6.0 g of concentrated glycerin, 0.1 g of dipotassium glycyrrhizinate, 0.1 g of allantoin, and 0.05 g of pyridoxine hydrochloride are added and dissolved in 75.72 g of purified water. Then 6.0 g of Lubrajel from Showa Denko K.K. (a mixture consisting of 4.674 g of purified water, 0.12 g of carboxy vinyl polymer, 0.006 g of sodium polyacrylate, and 1.2 g of glycerin), 0.44 g of carboxy vinyl polymer (product name: Carbopol 940, Lubrisol Advanced Materials, Inc.), and 8.00 g of 1% xanthan gum solution (product name: Keltrol T, CP Kelco) were added to this solution and stirred and mixed, then 0.04 g of natural vitamin E was further added to make a homogenous mixed solution. Finally, 0.25 g of potassium hydroxide was added for neutralization, and the solution was sufficiently stirred to form a gelled stat...

example 3

2. Production of CNP Aqueous-Solution Preparation

[0188]The CNP aqueous-solution preparation was prepared as follows: 3 mg of human CNP-22 (Peptide Institute, Inc.) as the principal agent was dissolved in 3 ml of saline, and 100 μl of the resulting solution was diluted with 900 μl of saline to prepare the aqueous-solution preparation with a CNP concentration of 100 μg / ml. CNP aqueous-solution preparations with a CNP concentration of 50 μg / ml and 200 μg / ml were prepared similarly.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
weight ratioaaaaaaaaaa
Login to View More

Abstract

The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects.The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

Description

FIELD OF INVENTION[0001]The present invention relates to a skin external-preparation composition comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as its active ingredient. In particular, the present invention relates to a therapeutic agent for skin disease or a skin texture-improving agent comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as its active ingredient.BACKGROUND ART1. Dermatitis:[0002]Dermatitis is an inflammatory reaction of the skin, and is the most prevalent skin disease. Often in acute skin inflammations, clinically, edematous erythema is presented initially, followed by erythematous lesions with papules and serous papules, then formation of vesicles, pustules, erosions, crusts and scales, followed by healing process. When a skin inflammation becomes chronic, thickened skin, lichenification and pigmentations are observed, and they are often associated with itching.[0003]Dermatitis includes contact dermatiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/22A61P37/08A61P17/00
CPCA61K8/64A61K9/0014A61K38/22A61K38/2242A61Q19/00A61K9/06A61Q1/02A61Q17/04A61Q19/10A61P17/00A61P17/02A61P17/04A61P17/06A61P17/08A61P17/10A61P17/14A61P17/16A61P17/18A61P29/00A61P31/10A61P31/22A61P37/08A61P43/00A61P7/10A61K9/70
Inventor ENDO, KYOKO
Owner IGISU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com